The<unk>  (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an<unk> -oncology drug.<unk> -oncology, part of the broader field of cancer<unk> therapy, involves agents which harness the body's own<unk>  system to fight cancer. Traditionally, patient<unk> s to new cancer treatments have been evaluated using two sets of<unk> , the WHO<unk>  and the<unk>  evaluation<unk>  in solid tumors (RECIST). The<unk> , first published in 2009, arose out of observations that<unk> -oncology drugs would fail in clinical trials that measured<unk> s using the WHO or RECIST<unk> , because these<unk>  could not account for the time gap in many patients between initial treatment and the apparent action of the<unk>  system to reduce the tumor burden.
Immune-related response criteria
Minimal residual disease
Clinical endpoint
Disease cluster
Predictive marker
Dose profile
Safety pharmacology
Toxicity category rating